Posted on

24 hour trip anyone?

MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program

Tripping on ibogaine can last over 24 hours, and it’s not always pleasant. But the wide range of benefits could make it worthwhile. 

MINDCURE (MCUR) hopes so at least. The company filed a provisional patent for synthetic ibogaine mixtures to treat various central nervous system disorders like:

  • Addiction
  • Traumatic brain injury
  • Anxiety disorders
  • Chronic pain such as migraines and cluster headaches

The company aims to be a global supplier of synthetic ibogaine for research purposes and expects to have supply available by the end of Q2 this year.

PDF of article

‍

Posted on

LSD and psilocybin have the same effects, apparently

MindMed Announces Publication of Study Comparing the Acute Effects of Lysergic Acid Diethylamide and Psilocybin in Healthy Subjects

MindMed’s latest study compared the experiences of LSD and psilocybin in high and low doses. 

Subjects were assessed on a scale that measures changes in consciousness like feelings of unity and bliss, ego dissolution, auditory and visual sensations, spiritual experiences, and insightfulness.

Researchers found “no evidence of qualitative differences in altered states of consciousness”  between the substances, except that LSD lasted longer. Any other differences could be attributed to the dose, not the substance.

They found that 20 mg psilocybin is equivalent to 100 µg LSD (a 1:200 ratio), and that body weight had no influence on the concentration of the drugs in blood plasma.

Posted on

Are psychedelics the key to a healthy family dynamic?

‘I Did Ayahuasca With My Parents And It Deepened Our Relationship’

To learn more about psychedelic medicine, Dr. Adele Lafrance attended an ayahuasca ceremony with her parents. It was so transformative that she’s planning to conduct studies on how psychedelics can support healthy family relationships.

She explains that the ceremony “planted the seeds for deeper emotional intimacy” and allowed her family to talk about love in a vulnerable way for the first time. The experience helped her heal from painful childhood memories.

“I felt a level of understanding toward my parents that was so deep, forgiveness wasn’t necessary. It was beautiful.”

PDF of article

Posted on

Help patients and clinicians fight for their right to psilocybin

Help TheraPsil-Supported Patients and Clinicians Fight for Legal Psilocybin

Our friends at TheraPsil helped 86 clinicians apply for Section 56 exemptions so they could participate in a psilocybin therapy training program.

Unfortunately, Health Canada denied the clinicians access to psilocybin, which will impact over 1500 patients who are desperately awaiting psilocybin treatments. Many Canadians will die before they have the chance to try psilocybin therapy.

TheraPsil needs our help to raise $100K to take the Canadian government to court to achieve lasting policy change so that Canadians can access the treatment before it’s too late. 

Support the cause here.

Therapsil
Posted on

World’s first DMT trial for depression

World’s First clinical trial for DMT-assisted therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I

Small Pharma (DMT) successfully completed a phase I trial on the safety of DMT in preparation for a phase II trial on depression. Researchers discovered that:

  • Most of the 24 patients described the experience as pleasurable and not too challenging (even though no one had tried psychedelics before)
  • Although there were 20 adverse events (85% mild, 15% moderate, and 0% severe), no patient regretted participating
  • The trip lasted 20 minutes, and DMT was nearly undetectable in the blood after 60 minutes
  • For three months following the dose, there were no significant negative effects on anxiety or well-being

Phase II results are expected in the first half of this year, which will reveal how one dose compares to two doses in treating depression.

PDF of article

Posted on

Acid-inspired invention earns Nobel Prize

The Nobel Prize-Winning, LSD Dropping, Yet Problematic Scientist Who Invented PCR

LSD led to the invention of a technology that has slowed the spread of Covid and even earned a Nobel Prize – the PCR test.

Chemist Kary Mullis experimented with lots of synthetic psychedelics, which is no surprise considering he was friends with Albert Hofmann, the creator of LSD. 

He believes psychedelics made him think more creatively and gave him visions of sitting on DNA molecules. When asked if he would have invented PCR technology without LSD, he responded, “I doubt it. I seriously doubt it.”

So this pandemic would likely be a lot longer if it weren’t for LSD!

PDF of article

Posted on

Making psilocybin for 1/100th the price

Vancouver discovery will make ‘Magic Mushroom’ mental health care cheaper

Producing psilocybin is wildly expensive if you want it to meet the FDA’s Good Manufacturing Practice (GMP) standards. With all the testing required, it can cost $7,000-$10,000 for a single gram of psilocybin.

Core One Labs (COOL) developed a new production method involving fermentation of bacteria that could reduce the cost of production to under $100 per gram. 

Hopefully this will make psilocybin therapy much more affordable!

PDF of article

Posted on

How psychedelics treat eye disease

PharmaDrug Receives Positive Results for DMT-Analogue Program to Treat Glaucoma

Glaucoma can cause irreversible vision loss and blindness. Current medications require multiple daily applications and have side effects like redness and stinging of the eyes.

PharmaDrug (PHRX) wants to develop a superior treatment using analogues of DMT.

The company discovered that the compounds can “activate protective pathways within critical cellular compartments of the eye” to reduce pressure inside the eye. 

PharmaDrug will collaborate with the Terasaki Institute for Biomedical Innovation to produce a device that can deliver low doses of the drug to the front of the eye. 

PDF of article

Posted on

What a DMT trip actually feels like

New study offers a detailed glimpse into the otherworldly encounters produced by the psychedelic drug DMT

Researchers interviewed 36 people immediately after a DMT trip. Here’s what they discovered:

  • All 36 people reported “entering other worlds”
  • 94% encountered some sort of otherworldly being or entity 
  • Entity encounters were overwhelmingly positive and often provided personal and cosmic insights (like self love or the game-like nature of reality)
  • 81% described the trip as “hyperreal” 

DMT increases theta brain waves, which are associated with dreaming, but it’s unclear why people have such similar “dreams” 🤔

PDF of article